Stay updated with breaking news from Start Codon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NK:IO, a leader in natural killer (NK) cell biology applied to the development of potent, off-the-shelf cell therapies targeting solid tumors, has raised £1.2m.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
New investment of £1.2M brings total Seed funding to £5.1M including Innovate UK grants of £1.9M.
Meet the most active investors in the European techbio scene — a challenging but rewarding sector for the VCs that are able to get into it
ArkVax, a spin out company from the London School of Hygiene & Tropical Medicine (LSHTM) has secured seed investment from Start Codon, a venture capital investor and venture builder based in Cambridge (UK). The investment will enable ArkVax to both grow its team and develop its vaccine platform technology to proof of concept, initially for use in animals.